Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC) - Fasching, Peter; Delea, T.; Lu, Y-S.; Deboer, R.; Hurvitz, S. A.; Moynahan, A.; Chandiwana, D.; Lanoue, B.; Hu, H.; Thuerigen, A.; O'Shaughnessy, J. (ANNALS OF ONCOLOGY, 2020)
CRIS-Team WoS Importer:2020-10-30